Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery

References

• Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol. 2008;83:359–362.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted county study, 1976–1995. Am J Hematol. 1999;61:10–15.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556–562.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66:549–556.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Fonseca R, Pereira DL, et al. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001;76:22–28.
   PubMed Web of Science ®Google Scholar
• Epstein E, Goedel A. Hämorrhagische thrombocythämie bei vasculärer schrumpfmilz. Virchows Arch path Anat. 1934;292:233–248.
   Google Scholar
• Fanger H, Cella LJ, Jr, Litchman H. Thrombocythemia; report of three cases and review of literature. N Engl J Med. 1954;250:456–461.
   PubMed Web of Science ®Google Scholar
• Ozer FL, Truax WE, Miesch DC, et al. Symposium on leukemia primary hemorrhagic thrombocythemia. Am J Med. 1960;28:807–823.
   PubMed Web of Science ®Google Scholar
• Murphy SI, H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the polycythemia vera study group. Semin Hematol. 1986;23:177–182.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790.
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T, et al. Mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–3476.
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123:3714–3719.
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–2390.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507–2513.
   PubMed Web of Science ®Google Scholar
• Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976;295:913–916.
   PubMed Web of Science ®Google Scholar
• Fialkow PJ, Faguet GB, Jacobson RJ, et al. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981;58:916–919.
   PubMed Web of Science ®Google Scholar
• Gaetani GF, Ferraris AM, Galiano S, et al. Primary thrombocythemia: clonal origin of platelets, erythrocytes, and granulocytes in a GdB/GdMediterranean subject. Blood. 1982;59:76–79.
   PubMed Web of Science ®Google Scholar
• Dai CH, Krantz SB, Dessypris EN, et al. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood. 1992;80:891–899.
   PubMed Web of Science ®Google Scholar
• Li Y, Hetet G, Maurer A-M, et al. Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF. Br J Haematol. 1994;87:471–476.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Teramura M, Hoshino S, et al. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3. Br J Haematol. 1993;83:539–544.
   PubMed Web of Science ®Google Scholar
• Axelrad AA, Eskinazi D, Correa PN, et al. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood. 2000;96:3310–3321.
   PubMed Web of Science ®Google Scholar
• Tortolani PJ, Johnston JA, Bacon CM, et al. Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2. Blood. 1995;85:3444–3451.
   PubMed Web of Science ®Google Scholar
• Marty C, Pecquet C, Nivarthi H, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127:1317–1324.
   PubMed Web of Science ®Google Scholar
• Chachoua I, Pecquet C, El-Khoury M, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2016;127:1325–1335.
   PubMed Web of Science ®Google Scholar
• Araki M, Yang Y, Masubuchi N, et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood. 2016;127:1307–1316.
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005;131:208–213.
   PubMed Web of Science ®Google Scholar
• Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007;109:2279–2284.
   PubMed Web of Science ®Google Scholar
• Cheung B, Radia D, Pantelidis P, et al. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol. 2006;132:244–245.
   PubMed Web of Science ®Google Scholar
• Zhang S, Qiu H, Fischer BS, et al. JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera. Leuk Lymphoma. 2008;49:696–699.
   PubMed Web of Science ®Google Scholar
• Toyama K, Karasawa M, Yamane A, et al. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Br J Haematol. 2007;139:64–69.
   PubMed Web of Science ®Google Scholar
• Wong RSM, Cheng C-K, Chan NPH, et al. JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia. Br J Haematol. 2008;141:902–904.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–1953.
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Ferretti V, et al. CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123:1544–1551.
   PubMed Web of Science ®Google Scholar
• Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123:1552–1555.
   PubMed Web of Science ®Google Scholar
• Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30:431–438.
   PubMed Web of Science ®Google Scholar
• Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127:333–342.
   PubMed Web of Science ®Google Scholar
• Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood 2016;127:325–332.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Iba S, Abe A, et al. Elongation of MPL transmembrane domain is a novel activating-mutation in essential thrombocythemia. Blood. 2015;126:1628–1628.
   Web of Science ®Google Scholar
• Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128–1138.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–2405.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke C, et al. Targeted next-generation sequencing in polycythemia vera and essential thrombocythemia. Blood. 2015;126:354–354.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21–30.
   PubMed Web of Science ®Google Scholar
• Gangat N, Tefferi A, Thanarajasingam G, et al. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol. 2009;83:17–21.
   PubMed Web of Science ®Google Scholar
• Sessarego M, Defferrari R, Dejana AM, et al. Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. Cancer Genet Cytogenet. 1989;43:57–65.
   PubMed Web of Science ®Google Scholar
• Panani AD. Cytogenetic findings in untreated patients with essential thrombocythemia. In Vivo. 2006;20:381–384.
   PubMed Web of Science ®Google Scholar
• Suleiman Y, Dalia S, Liu JJ, et al. Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia. Leukemia Res. 2016;42:52–58.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179–3184.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003;82:148–152.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol. 2002;70:283–291.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Müllauer L, et al. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117:5710–5718.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Jeryczynski G, Gisslinger B, et al. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia. 2016;30:1126–1132.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857–5859.
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–5133.
   PubMed Web of Science ®Google Scholar
• Haider M, Gangat N, Lasho T, et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am J Hematol. 2016;91:390–394.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93:1645–1651.
   PubMed Web of Science ®Google Scholar
• Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2006;21:270–276.
   PubMed Web of Science ®Google Scholar
• Abdulkarim K, Ridell B, Johansson P, et al. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol. 2011;86:148–155.
   PubMed Web of Science ®Google Scholar
• Chim C, Kwong Y, Lie A, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005;165:2651–2658.
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia. 2007;22:437–438.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–1132.
   PubMed Web of Science ®Google Scholar
• Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol. 1979;43:185–190.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larrán A, Talarn C, et al. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118:786–790.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Cervantes F, Bellosillo B, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21:1218–1223.
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81:159–166.
   PubMed Web of Science ®Google Scholar
• Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141–149.
   PubMed Web of Science ®Google Scholar
• Stein BL, Williams DM, O’Keefe C, et al. of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica. 2011;96:1462–1469.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755–761.
   PubMed Web of Science ®Google Scholar
• Rozman CE, F, Giralt M, Rubio D, et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991;67:2658–2663.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120:1197–1201.
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemianet. J Clin Oncol. 2011;29:761–770.
   PubMed Web of Science ®Google Scholar
• Rumi E, Cazzola M. How we treat essential thrombocythemia. Blood. 2016;128:2403–2414.
   PubMed Web of Science ®Google Scholar
• Besses CC, F, Pereira A, Florensa L, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13:150–154.
   PubMed Web of Science ®Google Scholar
• Budde UvG PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost. 1997;23:425–431.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients). Cancer. 2007;109:68–76.
   PubMed Web of Science ®Google Scholar
• Dueck AC, Geyer HL, Kiladjian J-J, et al. Myeloproliferative (MPN) symptom burden response thresholds: assessment of MPN-SAF TSS quartiles as potential markers of symptom response. Blood. 2013;122:4067–4067.
   Google Scholar
• Johansson P, Mesa R, Scherber R, et al. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk Lymphoma. 2012;53:441–444.
   PubMed Web of Science ®Google Scholar
• Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? ASH Educ Prog Book. 2014;2014:277–286.
   Google Scholar
• Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–124.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with CALR mutation. Haematologica. 2016;101:926–931.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132–1137.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121:1720–1728.
   PubMed Web of Science ®Google Scholar
• Mela Osorio MJ, Ferrari L, Goette NP, et al. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. Eur J Haematol. 2016;96:435–442.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013;122:893–901.
   PubMed Web of Science ®Google Scholar
• Verger E, Cassinat B, Chauveau A, et al. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015;126:2585–2591.
   PubMed Web of Science ®Google Scholar
• Gowin K, Thapaliya P, Samuelson J, et al. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica. 2012;97:1570–1573.
   PubMed Web of Science ®Google Scholar
• Stauffer Larsen T, Iversen KF, Hansen E, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leukemia Res. 2013;37:1041–1045.
   PubMed Web of Science ®Google Scholar
• Appelmann I, Kreher S, Parmentier S, et al. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). Ann Hematol. 2016;95:707–718.
   PubMed Web of Science ®Google Scholar
• Kander EM, Raza S, Zhou Z, et al. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. Int J Hematol. 2015;102:587–593.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26:716–719.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116:1205–1210.
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Van Genderen PJJ, Lindemans J, et al. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leuk Lymphoma. 1996;22:47–56.
   PubMed Web of Science ®Google Scholar
• Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev. 2010;24:227–232.
   PubMed Web of Science ®Google Scholar
• Greist A. The role of blood component removal in essential and reactive thrombocytosis. Therapher Dial. 2002;6:36–44.
   Web of Science ®Google Scholar
• Agarwal MB, Malhotra H, Chakrabarti P, et al. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian J Med Paediatr Oncol. 2015;36:3–16.
   PubMedGoogle Scholar
• Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol. 2001;66:152–159.
   PubMed Web of Science ®Google Scholar
• Lavi N, Brenner B, Avivi I, Management of pregnant women with myeloproliferative neoplasms. Thromb Res. 2013;131:S11–S13.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V > F) mutation. Blood 2007;110:485–489.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Robinson SE. Myeloproliferative disorders in pregnancy. Hematol Oncol Clin North Am. 2011;25:261–275.
   PubMed Web of Science ®Google Scholar
• Randi ML, Bertozzi I, Rumi E, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol. 2014;89:306–309.
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G. Myeloproliferative disease in pregnancy and other management issues. ASH Educ Prog Book. 2006;2006:246–252.
   Google Scholar
• Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016;175:31–36.
   PubMed Web of Science ®Google Scholar
• Rumi E, Bertozzi I, Casetti IC, et al. Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia. Haematologica. 2015;100:e443–e445.
   PubMed Web of Science ®Google Scholar
• Kreher S, Ochsenreither S, Trappe RU, et al. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol. 2014;93:1953–1963.
   PubMed Web of Science ®Google Scholar
• Beauverd Y, Radia D, Cargo C, et al. Pegylated interferon alpha-2a for essential thrombocythaemia during pregnancy, outcome and safety: a case series. Haematologica. 2016;101:e182–e184.
   PubMed Web of Science ®Google Scholar
• Hinds DA, Barnholt KE, Mesa RA, et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood. 2016;128:1121–1128.
   PubMed Web of Science ®Google Scholar
• Rumi E, Passamonti F, Pietra D, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006;107:2206–2211.
   PubMed Web of Science ®Google Scholar
• Bellanné-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108:346–352.
   PubMed Web of Science ®Google Scholar
• Rumi E, Harutyunyan AS, Pietra D, et al. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood. 2014;123:2416–2419.
   PubMed Web of Science ®Google Scholar
• Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103:4198–4200.
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Lund SH, Landgren O, et al. Survival in patients with familial and sporadic myeloproliferative neoplasms. Blood. 2015;125:3665–3666.
   PubMed Web of Science ®Google Scholar
• Stein BL, O’Brien S, Greenberg P, et al. The need for United States–based guidelines for myeloproliferative neoplasms. J Natl Compr Canc Netw. 2015;13:607–609.
   PubMed Web of Science ®Google Scholar
• Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373:920–928.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Passamonti F, Rambaldi A, et al. Long-term results from a phase II open-label study of ruxolitinib in patients with essential thrombocythemia refractory to or intolerant of hydroxyurea. Blood. 2014;124:1847.
   Web of Science ®Google Scholar